Ken Griffin Aravive, Inc. Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.25 - $1.92 $134,443 - $206,505	107,555 New	107,555 $135,000
Q4 2022 Feb 14, 2023	BUY	$1.2 - $1.83 $6,642 - $10,129	5,535 New	5,535 $7,000
Q2 2022 Aug 15, 2022	BUY	$0.93 - $1.9 $12,118 - $24,758	13,031 New	13,031 $13,000
Q1 2022 May 16, 2022	SELL	$1.85 - $2.75 $34,077 - $50,655	-18,420 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.19 - $4.07 $29,630 - $55,067	-13,530 Reduced 42.35%	18,420 $0
Q3 2021 Nov 15, 2021	SELL	$3.67 - $5.8 $67,105 - $106,053	-18,285 Reduced 36.4%	31,950 $119,000
Q2 2021 Aug 16, 2021	BUY	$4.65 - $6.42 $163,763 - $226,099	35,218 Added 234.52%	50,235 $0
Q1 2021 May 17, 2021	SELL	$5.11 - $9.24 $9,678 - $17,500	-1,894 Reduced 11.2%	15,017 $99,000
Q4 2020 Feb 16, 2021	BUY	$4.36 - $6.51 $24,263 - $36,228	5,565 Added 49.05%	16,911 $95,000
Q2 2020 Aug 14, 2020	BUY	$5.18 - $14.81 $58,772 - $168,034	11,346 New	11,346 $132,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.